Financial Ratios Hubei Jumpcan Pharmaceutical Co., Ltd.
Equities
600566
CNE0000018X6
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.59 CNY | -0.64% |
|
+0.26% | +1.10% |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 9.03 | 9.22 | 10.39 | 10.88 | 8.28 | |||||
Return on Total Capital | 11.51 | 11.52 | 13.1 | 13.75 | 10.1 | |||||
Return On Equity % | 18.42 | 20.33 | 21.2 | 22.87 | 18.06 | |||||
Return on Common Equity | 18.42 | 20.37 | 21.23 | 22.87 | 18.05 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 81.67 | 83.27 | 82.91 | 81.52 | 79.21 | |||||
SG&A Margin | 53.52 | 52.82 | 49.76 | 45.36 | 42.25 | |||||
EBITDA Margin % | 26.95 | 25.67 | 28.41 | 32.94 | 34.01 | |||||
EBITA Margin % | 22.68 | 22.09 | 25.26 | 30.07 | 30.53 | |||||
EBIT Margin % | 22.47 | 21.89 | 25.05 | 29.87 | 30.26 | |||||
Income From Continuing Operations Margin % | 20.72 | 22.5 | 24.14 | 29.28 | 31.64 | |||||
Net Income Margin % | 20.72 | 22.53 | 24.13 | 29.24 | 31.58 | |||||
Net Avail. For Common Margin % | 20.72 | 22.53 | 24.13 | 29.24 | 31.58 | |||||
Normalized Net Income Margin | 14.54 | 14.82 | 16.7 | 20.82 | 21.38 | |||||
Levered Free Cash Flow Margin | 14.74 | 13.27 | 18.23 | 23.6 | 16.17 | |||||
Unlevered Free Cash Flow Margin | 15.08 | 13.55 | 18.44 | 23.71 | 16.38 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.64 | 0.67 | 0.66 | 0.58 | 0.44 | |||||
Fixed Assets Turnover | 2 | 2.47 | 3.05 | 3.34 | 2.85 | |||||
Receivables Turnover (Average Receivables) | 3.01 | 3.61 | 3.57 | 3.42 | 3.17 | |||||
Inventory Turnover (Average Inventory) | 3.66 | 3.9 | 4.01 | 4.05 | 3.15 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 3.34 | 2.9 | 3.26 | 3.1 | 4.16 | |||||
Quick Ratio | 3.18 | 2.75 | 3.13 | 2.99 | 3.99 | |||||
Operating Cash Flow to Current Liabilities | 0.91 | 0.68 | 0.76 | 0.75 | 0.62 | |||||
Days Sales Outstanding (Average Receivables) | 121.58 | 100.97 | 102.33 | 106.64 | 115.32 | |||||
Days Outstanding Inventory (Average Inventory) | 99.88 | 93.5 | 91.06 | 90.18 | 116.31 | |||||
Average Days Payable Outstanding | 151.95 | 153.83 | 287.97 | 353.45 | 405.85 | |||||
Cash Conversion Cycle (Average Days) | 69.51 | 40.64 | -94.59 | -156.62 | -174.22 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 7.76 | 6.9 | 3.53 | 8.15 | 5.69 | |||||
Total Debt / Total Capital | 7.2 | 6.46 | 3.41 | 7.54 | 5.39 | |||||
LT Debt/Equity | 7.76 | 0.01 | 0 | 0.01 | 0.01 | |||||
Long-Term Debt / Total Capital | 7.2 | 0.01 | 0 | 0.01 | 0.01 | |||||
Total Liabilities / Total Assets | 26.18 | 24.73 | 24.22 | 26.32 | 20.22 | |||||
EBIT / Interest Expense | 41.94 | 47.87 | 74.12 | 163.99 | 88.94 | |||||
EBITDA / Interest Expense | 50.31 | 56.15 | 84.11 | 180.95 | 100.03 | |||||
(EBITDA - Capex) / Interest Expense | 37.3 | 49.04 | 76.1 | 163.8 | 93.64 | |||||
Total Debt / EBITDA | 0.36 | 0.32 | 0.16 | 0.34 | 0.31 | |||||
Net Debt / EBITDA | -2.18 | -2.48 | -2.92 | -3.09 | -4.03 | |||||
Total Debt / (EBITDA - Capex) | 0.49 | 0.37 | 0.17 | 0.38 | 0.33 | |||||
Net Debt / (EBITDA - Capex) | -2.93 | -2.84 | -3.22 | -3.41 | -4.3 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -11.17 | 23.77 | 17.9 | 7.32 | -16.96 | |||||
Gross Profit, 1 Yr. Growth % | -13.64 | 26.2 | 17.39 | 5.52 | -19.31 | |||||
EBITDA, 1 Yr. Growth % | -18.35 | 17.58 | 30.17 | 24.19 | -14.38 | |||||
EBITA, 1 Yr. Growth % | -23.44 | 20.17 | 34.43 | 27.52 | -15.82 | |||||
EBIT, 1 Yr. Growth % | -23.15 | 20.6 | 34.91 | 27.94 | -15.88 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -21.3 | 34.45 | 26.47 | 30.18 | -10.27 | |||||
Net Income, 1 Yr. Growth % | -21.3 | 34.6 | 26.27 | 30.04 | -10.32 | |||||
Normalized Net Income, 1 Yr. Growth % | -21.86 | 26.15 | 32.83 | 33.79 | -14.75 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -23.12 | 24.84 | 25.13 | 28.87 | -10.39 | |||||
Accounts Receivable, 1 Yr. Growth % | -1.12 | 7.44 | 30.58 | -2.41 | -18.84 | |||||
Inventory, 1 Yr. Growth % | -17.74 | 34.9 | 4.23 | 25.19 | 16.12 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 4.07 | -3.4 | -5.86 | 2.32 | -7.4 | |||||
Total Assets, 1 Yr. Growth % | 21.36 | 15.36 | 23.49 | 21.11 | 1.74 | |||||
Tangible Book Value, 1 Yr. Growth % | 30.54 | 18.57 | 25.14 | 18.69 | 10.47 | |||||
Common Equity, 1 Yr. Growth % | 27.17 | 17.44 | 24.36 | 17.75 | 10.13 | |||||
Cash From Operations, 1 Yr. Growth % | -17.04 | 6.32 | 38.35 | 32.17 | -37.17 | |||||
Capital Expenditures, 1 Yr. Growth % | -21.38 | -42.2 | -1.88 | 23.8 | -42.21 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -30.2 | 11.37 | 61.99 | 38.92 | -43.09 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -29.65 | 11.24 | 60.42 | 37.99 | -42.62 | |||||
Dividend Per Share, 1 Yr. Growth % | -63.41 | 51.11 | 29.41 | 47.73 | 60.77 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -7.52 | 4.86 | 20.8 | 12.48 | -5.6 | |||||
Gross Profit, 2 Yr. CAGR % | -9.24 | 4.4 | 21.72 | 11.3 | -7.73 | |||||
EBITDA, 2 Yr. CAGR % | -9.79 | -1.89 | 23.86 | 27.26 | 3.19 | |||||
EBITA, 2 Yr. CAGR % | -13.97 | -3.93 | 27.27 | 31.07 | 3.69 | |||||
EBIT, 2 Yr. CAGR % | -13.85 | -3.73 | 27.56 | 31.38 | 3.74 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -13.01 | 2.86 | 30.4 | 28.31 | 8.08 | |||||
Net Income, 2 Yr. CAGR % | -13.01 | 2.92 | 30.37 | 28.14 | 7.99 | |||||
Normalized Net Income, 2 Yr. CAGR % | -12.8 | -0.71 | 29.45 | 33.31 | 6.8 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -14.03 | -2.03 | 24.98 | 26.99 | 7.46 | |||||
Accounts Receivable, 2 Yr. CAGR % | -1.78 | 3.07 | 18.45 | 12.88 | -11 | |||||
Inventory, 2 Yr. CAGR % | -6.45 | 5.34 | 18.58 | 14.23 | 20.57 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 5.64 | 0.26 | -4.64 | -1.86 | -2.66 | |||||
Total Assets, 2 Yr. CAGR % | 16.13 | 18.32 | 19.36 | 22.3 | 11 | |||||
Tangible Book Value, 2 Yr. CAGR % | 21.3 | 24.41 | 21.81 | 21.87 | 14.51 | |||||
Common Equity, 2 Yr. CAGR % | 19.26 | 22.21 | 20.85 | 21.01 | 13.88 | |||||
Cash From Operations, 2 Yr. CAGR % | 2.1 | -6.08 | 21.28 | 35.23 | -8.87 | |||||
Capital Expenditures, 2 Yr. CAGR % | -19.81 | -32.59 | -24.69 | 10.22 | -15.41 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 146.14 | -11.83 | 34.32 | 50.01 | -11.09 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 132.91 | -11.54 | 33.59 | 48.78 | -11.02 | |||||
Dividend Per Share, 2 Yr. CAGR % | -39.51 | -25.65 | 39.84 | 38.27 | 54.11 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 3 | 1.92 | 9.04 | 16.13 | 1.66 | |||||
Gross Profit, 3 Yr. CAGR % | 1.65 | 1.3 | 8.56 | 16.06 | -0.02 | |||||
EBITDA, 3 Yr. CAGR % | 3.45 | -1.37 | 7.9 | 24.05 | 11.56 | |||||
EBITA, 3 Yr. CAGR % | 0.7 | -3.73 | 7.55 | 27.45 | 13.14 | |||||
EBIT, 3 Yr. CAGR % | 0.88 | -3.63 | 7.73 | 27.69 | 13.24 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 1.43 | 0.58 | 10.2 | 30.32 | 13.89 | |||||
Net Income, 3 Yr. CAGR % | 1.44 | 0.61 | 10.18 | 30.26 | 13.77 | |||||
Normalized Net Income, 3 Yr. CAGR % | 0.04 | -1.37 | 9.4 | 30.88 | 14.85 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 0.44 | -2.65 | 6.3 | 26.27 | 13.06 | |||||
Accounts Receivable, 3 Yr. CAGR % | 4.01 | 1.2 | 11.53 | 11.04 | 1.13 | |||||
Inventory, 3 Yr. CAGR % | 4.72 | 5.69 | 4.97 | 20.74 | 14.86 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 10.62 | 2.54 | -1.82 | -2.37 | -3.74 | |||||
Total Assets, 3 Yr. CAGR % | 16.43 | 15.87 | 20.02 | 19.94 | 15.02 | |||||
Tangible Book Value, 3 Yr. CAGR % | 22.15 | 20.38 | 24.65 | 20.76 | 17.95 | |||||
Common Equity, 3 Yr. CAGR % | 20.82 | 18.65 | 22.92 | 19.8 | 17.27 | |||||
Cash From Operations, 3 Yr. CAGR % | 14.44 | 3.49 | 6.86 | 24.81 | 4.74 | |||||
Capital Expenditures, 3 Yr. CAGR % | -16.81 | -28.1 | -23.6 | -11.12 | -11.12 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 128.96 | 88.96 | 7.99 | 35.83 | 8.59 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 127.32 | 82.06 | 7.88 | 35.04 | 8.3 | |||||
Dividend Per Share, 3 Yr. CAGR % | -23.37 | -17.93 | -10.56 | 42.42 | 45.39 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 10.35 | 10.28 | 9.78 | 6.02 | 2.93 | |||||
Gross Profit, 5 Yr. CAGR % | 9.64 | 9.77 | 9.25 | 5.19 | 1.73 | |||||
EBITDA, 5 Yr. CAGR % | 14.42 | 11.12 | 11.23 | 9.27 | 6.03 | |||||
EBITA, 5 Yr. CAGR % | 13.04 | 9.76 | 10.66 | 8.98 | 6.04 | |||||
EBIT, 5 Yr. CAGR % | 13.4 | 9.96 | 10.81 | 9.09 | 6.12 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 13.33 | 12.94 | 12.15 | 10.87 | 9.34 | |||||
Net Income, 5 Yr. CAGR % | 13.22 | 12.97 | 12.15 | 10.83 | 9.3 | |||||
Normalized Net Income, 5 Yr. CAGR % | 13.52 | 11.37 | 10.9 | 11.26 | 8.35 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 11.7 | 10.3 | 9.62 | 8.27 | 6.76 | |||||
Accounts Receivable, 5 Yr. CAGR % | 12.58 | 8.89 | 9.56 | 5.72 | 1.9 | |||||
Inventory, 5 Yr. CAGR % | 10.29 | 12.94 | 10.06 | 9.02 | 10.95 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 18.32 | 12.38 | 4.24 | 0.76 | -2.16 | |||||
Total Assets, 5 Yr. CAGR % | 24.01 | 19.45 | 17.59 | 18.4 | 16.33 | |||||
Tangible Book Value, 5 Yr. CAGR % | 26.13 | 21.57 | 22.01 | 20.98 | 20.49 | |||||
Common Equity, 5 Yr. CAGR % | 23.81 | 20.04 | 20.83 | 19.59 | 19.22 | |||||
Cash From Operations, 5 Yr. CAGR % | 22.52 | 15.71 | 17.13 | 15.18 | 0.27 | |||||
Capital Expenditures, 5 Yr. CAGR % | 1.64 | -5.15 | -20.06 | -14.7 | -20.43 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 213.2 | 15.4 | 84.98 | 72.3 | -0.09 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 256.64 | 15.89 | 83.77 | 67.94 | -0.12 | |||||
Dividend Per Share, 5 Yr. CAGR % | -8.46 | -1.41 | -2.52 | 1.11 | 11.19 |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















